Xeris Biopharma Holdings Inc [NASDAQ: XERS] gained 11.95% on the last trading session, reaching $5.34 price per share at the time.
Xeris Biopharma Holdings Inc represents 156.01 million in outstanding shares, while the company has a total market value of $855.23 million with the latest information. XERS stock price has been found in the range of $4.82 to $5.36.
If compared to the average trading volume of 2.25M shares, XERS reached a trading volume of 4679732 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Xeris Biopharma Holdings Inc [XERS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for XERS shares is $6.30 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on XERS stock is a recommendation set at 1.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Xeris Biopharma Holdings Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 11, 2024. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on March 28, 2024, representing the official price target for Xeris Biopharma Holdings Inc stock. Previously, the target price had yet another raise to $4.50, while Craig Hallum analysts kept a Buy rating on XERS stock.
Trading performance analysis for XERS stock
Xeris Biopharma Holdings Inc [XERS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.59. With this latest performance, XERS shares gained by 16.59% in over the last four-week period, additionally plugging by 47.92% over the last 6 months – not to mention a rise of 57.52% in the past year of trading.
Xeris Biopharma Holdings Inc [XERS]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Xeris Biopharma Holdings Inc [XERS] shares currently have an operating margin of -10.11% and a Gross Margin at 77.34%. Xeris Biopharma Holdings Inc’s Net Margin is presently recorded at -20.25%.
Return on Equity for this stock declined to -13.83%, with Return on Assets sitting at -13.83%.
An analysis of Institutional ownership at Xeris Biopharma Holdings Inc [XERS]
There are presently around $54.50%, or 56.88% of XERS stock, in the hands of institutional investors. The top three institutional holders of XERS stocks are: BLACKROCK INC. with ownership of 10.33 million shares, which is approximately 6.9649%. VANGUARD GROUP INC, holding 7.66 million shares of the stock with an approximate value of $$17.23 million in XERS stocks shares; and VANGUARD GROUP INC, currently with $$11.51 million in XERS stock with ownership which is approximately 3.4469%.
